Clinical Trials Update: June 27, 2005
Genital Herpes Menstrual Disorders Cancer/Tumors
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
One in four people 18 years or older in the US is infected with genital herpes. Symptoms could included itching, tingling, or burning sensations, blisters, or raised red bumps in the genital area that irritate, itch or cause pain. Research site located in San Antonio, Texas.
Phoenix Ob Gyn Associates, LLC. is looking for women to participate in a study of an investigational medicine for heavy menstrual bleeding. This investigational drug is not a hormone. To qualify, you must be a generally healthy woman between the ages of 18 and 49, have regular menstrual cycles with heavy bleeding, and not have any other bleeding disorder. Research site located in Moorestown, NJ.
BAY 43-9006 is an investigational drug being studied as a potential treatment for hepatocellular carcinoma. A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma is being conducted in 23 countries to evaluate the safety and efficacy of BAY 43-9006. Participants will be male or female patients at least 18 years of age with a life expectancy of at least 12 weeks, diagnosed with advanced HCC, with at least one tumor lesion that meets the following criteria: accurately measured in at least one dimension according to RECIST and not previously treated with local therapy. Research sites located in California and Virginia.
Copyright 2005 CenterWatch. All rights reserved.